Money Concepts Capital’s Cue Biopharma CUE Stock Holding History

Money Concepts Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-24	Closed	-$2.04K	–	978
2022 Q4	$2.04K	Buy	+24	New	+$2.19K	﹤0.01%	2680

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Money Concepts Capital's CUE Position: Q1 2023 in Review

Money Concepts Capital sold out of Cue Biopharma (CUE) in Q1 2023, closing a stake of 24 shares — an estimated $2.04K sold.

Money Concepts Capital first reported a position in CUE in Q4 2022 and held it in 1 quarter. The position peaked at $2.04K in Q4 2022. 63 funds tracked by Wall St. Rank hold CUE as of Q1 2023.

Money Concepts Capital reported no remaining Cue Biopharma position as of Q1 2023 after selling out during the quarter.
Money Concepts Capital sold 24 Cue Biopharma shares in Q1 2023, an estimated $2.04K.
Money Concepts Capital first reported a position in Cue Biopharma in Q4 2022 and held it in 1 quarter.
Money Concepts Capital's Cue Biopharma position peaked at $2.04K in Q4 2022.
63 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.